BioSpecifics Technologies Corp
BioSpecifics Technologies — Investor Presentation (January 2020)
16 slides from BioSpecifics Technologies's investor presentation, Jan 13, 2020
Slide 1: Building a next-generation company upon the foundation of our collagenase-based therapies
Exhibit 99.1 Building a next-generation company upon the foundation of our collagenase-based therapies JANUARY 2020Exhibit 99.1 Building a next-generation company upon the foundation of our collagenase-based therapies JANUARY 2020
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding
Slide 3: Deep CCH Commercial and Development Pipeline
Deep CCH Commercial and Development Pipeline Biopharmaceutical company that originated and continues to develop, in collaboration with Endo Pharmaceuticals, a specific collagenase formulation, collagenase clostridium histolyticum (CCH) Collagenases are Collagen is the main structural Local accumulat
Slide 4: Multiple Conditions Associated with Collagen Accumulation
Multiple Conditions Associated with Collagen Accumulation Approved indications, • Dupuytren’s contracture marketed as XIAFLEX • Peyronie’s disease • Cellulite Filed for FDA approval • Adhesive Capsulitis Potential future (frozen shoulder) indications include • Plantar Fibromatosis • Uterine Fibroids
Slide 5: Profitable Company with Strong Balance Sheet to Support Future Growth Initiatives
Profitable Company with Strong Balance Sheet to Support Future Growth Initiatives Profitable with lean corporate structure and strong balance sheet Seeking to partner with companies that possess ~$98M $9.4M 0 interesting new technologies in cash as of 9/30/19 3Q19 royalties Debt and products in rela
Slide 6: Diverse Development Pipeline
Diverse Development Pipeline Indication Preclinical Phase 1 Phase 2 Phase 3 Marketed APPROVED INDICATIONS Dupuytren’s Contracture Peyronie’s Disease FILED FOR APPROVAL Cellulite POTENTIAL FUTURE INDICATIONS Adhesive Capsulitis Uterine Fibroids Plantar Fibromatosis Source: Endo International plc 6Div
Slide 7: Marketed XIAFLEX Indications
® Marketed XIAFLEX Indications 7® Marketed XIAFLEX Indications 7
Slide 8: Peyronie's Disease
Peyronie’s Disease • Can distort an erection and make sexual intercourse difficult or even impossible in advanced cases Characterized by presence • In some mild cases, the plaque can resolve of a collagen plaque on spontaneously without medical intervention the shaft of the penis • In severe cases,
Slide 9: Dupuytren's Contracture
Dupuytren’s Contracture • Onset is characterized by the formation of nodules at the juncture between the fingers and palm that Deforming condition of are composed primarily of collagen the hand in which one • As the disease progresses, collagen nodules begin to or more fingers contract form a cord c
Slide 10: CCH Development Pipeline
CCH Development Pipeline 10CCH Development Pipeline 10
Slide 11: Cellulite
Cellulite • Affects ~85-90% of post-pubertal females • Currently no FDA approved pharmaceutical Skin dimpling occurring products to address fibrous septae primarily mainly on the buttocks, composed of collagen thighs and lower abdomen • Total U.S. aesthetics market $15B, and arms total U.S. aestheti
Slide 12: Uterine Fibroids
Uterine Fibroids • Cause pelvic discomfort and pain, decreased fertility, pregnancy complications, increased rate Benign tumors in the of miscarriage, uterine bleeding, prolonged reproductive tract that menstrual bleeding and frequent urination contain large amounts • Leading cause of hysterectomies
Slide 13: BSTC Corporate Overview
BSTC Corporate Overview 13BSTC Corporate Overview 13
Slide 14: Profitable on an Ongoing Basis: Financial Highlights from 3Q19
Profitable on an Ongoing Basis: Financial Highlights from 3Q19 For the nine months ended (unaudited) 09/30/2019 09/30/2018 Cash and equivalents, and investments $98,351,545 $76,978,545 Income Statement Revenues $26,424,380 $23,108,264 Other income 1,471,489 947,997 Costs and expenses (7,067,404) (6,
Slide 15: Corporate Outlook and Upcoming Milestones
Corporate Outlook and Upcoming Milestones Continue to receive royalty Opportunistic about Continue to advance revenues from partner Endo Business Development diverse development for both marketed XIAFLEX opportunities pipeline indications; Peyronie’s • Expanding BioSpecifics • BLA for cellulite acce
Slide 16: Building a next-generation company upon the foundation of our collagenase-based therapies
Building a next-generation company upon the foundation of our collagenase-based therapies JANUARY 2020Building a next-generation company upon the foundation of our collagenase-based therapies JANUARY 2020
Biospecifics Technologies — Investor Presentation (January 2020) on 6ix